View ValuationJeonjinbio 将来の成長Future 基準チェック /06現在、 Jeonjinbioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長66.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₩2,450, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.お知らせ • Mar 11Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,848, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years.分析記事 • Nov 21Returns At Jeonjinbio (KOSDAQ:110020) Are On The Way UpIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...New Risk • Oct 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩24.9b market cap, or US$17.5m).分析記事 • Sep 03The Price Is Right For Jeonjinbio Co., Ltd. (KOSDAQ:110020) Even After Diving 28%Unfortunately for some shareholders, the Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has dived 28% in the last...分析記事 • Jul 24Returns On Capital Are Showing Encouraging Signs At Jeonjinbio (KOSDAQ:110020)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,260, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 19% over the past three years.New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.9b market cap, or US$22.7m).Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,630, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Market cap is less than US$100m (₩20.3b market cap, or US$14.8m).分析記事 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...お知らせ • Mar 06Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South KoreaValuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩2,885, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years.分析記事 • Jan 07Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price In Tune With RevenuesWhen close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.6x...New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩21.3b market cap, or US$14.5m).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩24.5b market cap, or US$17.0m).分析記事 • Oct 25There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...お知らせ • Jun 15Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun.Dabin BNS Co., Ltd. agreed to acquire 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun for KRW 22 billion on October 13, 2023. The transaction is expected to close on November 24, 2023. As on November 24, 2023, the transaction is expected to close on December 15, 2023. The transaction is expected to complete on March 28, 2024. The transaction is expected to complete on May 9, 2024. The transaction is expected to complete on May 30, 2024. As of May 30, 2024, the transaction is expected to close on June 5, 2024. The transaction is expected to complete on June 07, 2024. As of June 7, 2024, the transaction is expected to close on June 13, 2024.Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun on June 13, 2024.分析記事 • Jun 07With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay ForThe Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has fared very poorly over the last month, falling by a...New Risk • Jun 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩33.4b market cap, or US$24.4m).Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.お知らせ • May 09Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million.Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million. Security Name: Shares Security Type: Common Stock Securities Offered: 188,679 Price\Range: KRW 5300 Transaction Features: Subsequent Direct Listing分析記事 • Apr 03Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) PriceJeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) price-to-sales (or "P/S") ratio of 3.7x may look like a poor investment...New Risk • Oct 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩63.6b market cap, or US$46.8m).New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩40.4b market cap, or US$30.5m).New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩37.0b market cap, or US$29.3m).分析記事 • Apr 13Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Mar 07New 90-day high: ₩12,700The company is up 2.0% from its price of ₩12,500 on 07 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.分析記事 • Feb 19If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% ReturnsWhile Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Dec 08New 90-day low: ₩9,900The company is down 9.0% from its price of ₩10,900 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).Is New 90 Day High Low • Oct 08New 90-day high: ₩15,300The company is up 174% from its price of ₩5,580 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.Is New 90 Day High Low • Sep 22New 90-day high: ₩12,800The company is up 163% from its price of ₩4,860 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.お知らせ • Jun 20Jeonjinbio Co., Ltd. announced that it has received KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment ArmOn June 18, 2020, Jeonjinbio Co., Ltd. (KOSDAQ:A110020) closed the transaction.お知らせ • Jun 18Jeonjinbio Co., Ltd. announced that it expects to receive KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm and other investorsJeonjinbio Co., Ltd. (KOSDAQ:A110020) announced a private placement of 7th series unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 3,500,000,000 on June 16, 2020. The bonds have a coupon rate of 1% and maturity date of June 18, 2023. The bonds are convertible into 702,106 common shares representing 14.64% stake at a conversion price of KRW 4,985 and the conversion period of the bonds will start from June 18, 2021 and end on May 18, 2023. The transaction will include participation from KB Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Gicheol Oh for KRW 1,000,000,000, JooEun Seo for KRW 300,000,000 and Geun-bae Kim for KRW 200,000,000. The transaction has been approved by the board of directors of the company. The payment date and subscription date of the transaction is June 18, 2020. The bonds are subject to prohibition of exercise for 1 year and prohibition of division/merging. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Jeonjinbio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A110020 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202614,421171,0291,699N/A12/31/202513,694-196-308483N/A9/30/202514,654728-358505N/A6/30/202515,4519561,2542,108N/A3/31/202517,0224,2451,7191,966N/A12/31/202419,2734,3462,6113,005N/A9/30/202419,9599782,1902,877N/A6/30/202419,142-2016411,392N/A3/31/202417,686-5,550-538239N/A12/31/202315,681-6,440-972-301N/A9/30/202313,204-4,327-2,280-1,263N/A6/30/202310,893-4,905-3,590-2,355N/A3/31/20239,055-2,999-4,441-2,518N/A12/31/20227,794-3,113-5,839-3,710N/A9/30/20225,899-2,504-5,214-3,811N/A6/30/20224,557-2,228-4,631-3,509N/A3/31/20223,457-2,462-2,828-2,363N/A12/31/20213,214-2,108-4,318-2,385N/A9/30/20213,496-3,609-5,978-2,665N/A6/30/20213,796-3,275-7,682-3,215N/A3/31/20213,910-3,882-8,382-3,369N/A12/31/20203,867-3,418-8,147-2,310N/A9/30/20204,732-1,604-6,438-1,637N/A6/30/20204,643-1,648-4,798-926N/A3/31/20204,426-1,330-3,836-501N/A12/31/20193,949-1,462N/A-1,299N/A9/30/20192,230-3,437N/A-2,330N/A6/30/20191,357-3,579N/A-2,721N/A3/31/20191,243-3,495N/A-2,908N/A12/31/20181,384-3,399N/A-2,161N/A9/30/20182,216-3,610N/A-1,133N/A6/30/20182,392-3,366N/A-846N/A3/31/20182,792-3,130N/A-586N/A12/31/20173,136-3,041N/A-413N/A9/30/20172,645-2,626N/A-429N/A6/30/20173,106-3,325N/A-241N/A3/31/20172,895-3,697N/A166N/A12/31/20164,809-3,074N/A-182N/A12/31/20152,018-2,931N/A-1,953N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A110020の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A110020の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A110020の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A110020の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A110020の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A110020の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 07:30終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jeonjinbio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₩2,450, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.
お知らせ • Mar 11Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026Jeonjinbio Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩1,848, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years.
分析記事 • Nov 21Returns At Jeonjinbio (KOSDAQ:110020) Are On The Way UpIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Risk • Oct 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩24.9b market cap, or US$17.5m).
分析記事 • Sep 03The Price Is Right For Jeonjinbio Co., Ltd. (KOSDAQ:110020) Even After Diving 28%Unfortunately for some shareholders, the Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has dived 28% in the last...
分析記事 • Jul 24Returns On Capital Are Showing Encouraging Signs At Jeonjinbio (KOSDAQ:110020)There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,260, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 19% over the past three years.
New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩30.9b market cap, or US$22.7m).
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,630, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 41% over the past three years.
New Risk • May 23New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (25% accrual ratio). Minor Risk Market cap is less than US$100m (₩20.3b market cap, or US$14.8m).
分析記事 • Mar 14We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...
お知らせ • Mar 06Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025Jeonjinbio Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 295, seongseogongdanbuk-ro, dalseo-gu, daegu South Korea
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩2,885, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years.
分析記事 • Jan 07Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price In Tune With RevenuesWhen close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.6x...
New Risk • Dec 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩21.3b market cap, or US$14.5m).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩24.5b market cap, or US$17.0m).
分析記事 • Oct 25There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
お知らせ • Jun 15Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun.Dabin BNS Co., Ltd. agreed to acquire 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun for KRW 22 billion on October 13, 2023. The transaction is expected to close on November 24, 2023. As on November 24, 2023, the transaction is expected to close on December 15, 2023. The transaction is expected to complete on March 28, 2024. The transaction is expected to complete on May 9, 2024. The transaction is expected to complete on May 30, 2024. As of May 30, 2024, the transaction is expected to close on June 5, 2024. The transaction is expected to complete on June 07, 2024. As of June 7, 2024, the transaction is expected to close on June 13, 2024.Dabin BNS Co., Ltd. cancelled the acquisition of 7.42% stake in Jeonjinbio Co., Ltd. (KOSDAQ:A110020) from Lee Tae Hoon and Woo Sang Hyun on June 13, 2024.
分析記事 • Jun 07With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay ForThe Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has fared very poorly over the last month, falling by a...
New Risk • Jun 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩33.4b market cap, or US$24.4m).
Reported Earnings • May 19First quarter 2024 earnings released: ₩36.00 loss per share (vs ₩169 loss in 1Q 2023)First quarter 2024 results: ₩36.00 loss per share (improved from ₩169 loss in 1Q 2023). Revenue: ₩4.41b (up 84% from 1Q 2023). Net loss: ₩282.3m (loss narrowed 76% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.
お知らせ • May 09Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million.Jeonjinbio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.9987 million. Security Name: Shares Security Type: Common Stock Securities Offered: 188,679 Price\Range: KRW 5300 Transaction Features: Subsequent Direct Listing
分析記事 • Apr 03Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) PriceJeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) price-to-sales (or "P/S") ratio of 3.7x may look like a poor investment...
New Risk • Oct 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩63.6b market cap, or US$46.8m).
New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 0.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.6b free cash flow). Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Market cap is less than US$100m (₩40.4b market cap, or US$30.5m).
New Risk • Jul 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.4b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (₩37.0b market cap, or US$29.3m).
分析記事 • Apr 13Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Mar 07New 90-day high: ₩12,700The company is up 2.0% from its price of ₩12,500 on 07 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.
分析記事 • Feb 19If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% ReturnsWhile Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Dec 08New 90-day low: ₩9,900The company is down 9.0% from its price of ₩10,900 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: ₩120 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: ₩1.08b (up 8.9% from 3Q 2019). Net loss: ₩577.5m (loss narrowed 7.2% from 3Q 2019).
Is New 90 Day High Low • Oct 08New 90-day high: ₩15,300The company is up 174% from its price of ₩5,580 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.
Is New 90 Day High Low • Sep 22New 90-day high: ₩12,800The company is up 163% from its price of ₩4,860 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
お知らせ • Jun 20Jeonjinbio Co., Ltd. announced that it has received KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment ArmOn June 18, 2020, Jeonjinbio Co., Ltd. (KOSDAQ:A110020) closed the transaction.
お知らせ • Jun 18Jeonjinbio Co., Ltd. announced that it expects to receive KRW 3.5 billion in funding from KB Securities Co., Ltd., Investment Arm and other investorsJeonjinbio Co., Ltd. (KOSDAQ:A110020) announced a private placement of 7th series unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 3,500,000,000 on June 16, 2020. The bonds have a coupon rate of 1% and maturity date of June 18, 2023. The bonds are convertible into 702,106 common shares representing 14.64% stake at a conversion price of KRW 4,985 and the conversion period of the bonds will start from June 18, 2021 and end on May 18, 2023. The transaction will include participation from KB Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, Gicheol Oh for KRW 1,000,000,000, JooEun Seo for KRW 300,000,000 and Geun-bae Kim for KRW 200,000,000. The transaction has been approved by the board of directors of the company. The payment date and subscription date of the transaction is June 18, 2020. The bonds are subject to prohibition of exercise for 1 year and prohibition of division/merging.